-+ 0.00%
-+ 0.00%
-+ 0.00%

Hemab Therapeutics Hldgs Q2 EPS $(0.80) Misses $(0.52) Estimate

Benzinga·08/11/2026 11:07:09
Listen to the news
Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.52) by 53.85 percent. This is a 93.8 percent increase over losses of $(12.91) per share from the same period last year.